Roivant Sciences (ROIV) Divestments (2023 - 2024)
Roivant Sciences' (ROIV) quarterly Divestments came in at $185.6 million in Q4 2024, up 290.71% YoY from $47.5 million in Q1 2024, and up 290.71% on a QoQ basis from $47.5 million in Q4 2023.
Roivant Sciences (ROIV) Divestments (2023 - 2024) Analysis & Trends
Roivant Sciences (ROIV) has 2 years of Divestments data on file, last reported at $185.6 million in Q4 2024.
- Quarterly Divestments rose 290.71% year-over-year to $185.6 million in Q4 2024, while the trailing twelve-month figure through Dec 2025 was $233.1 million (changed N/A YoY) and the FY2025 annual result came in at $260.6 million, up 448.6% from the prior year.
- Divestments advanced to $185.6 million in Q4 2024, from $47.5 million in the prior quarter.
- In the past five years, Divestments ranged from a high of $185.6 million in Q4 2024 to a low of $47.5 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Divestments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 9.82 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -13.21 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 185.59 Mn |
| Dec 31, 2023 | 47.50 Mn |